Vancouver-based AbCellera Biologics will receive up to $175.6 million from the federal Strategic Innovation Fund to fast-track antibody therapies against COVID-19. The funding will also go to build a first-of-its-kind antibody manufacturing facility over the next four years to help Canada respond to future pandemics. AbCellera has partnered with global biopharmaceutical company Eli Lilly to…
Person: Charu Kaushic
Ottawa moves with “unprecedented” speed to fast-track COVID-19 research
In collaborating with the WHO and other governments, Canada’s funding agencies have moved rapidly to channel more than $52 million in federal funding to rapid response research at Canadian universities.